160 related articles for article (PubMed ID: 34709591)
1. Lonapegsomatropin: Pediatric First Approval.
Lamb YN
Paediatr Drugs; 2022 Jan; 24(1):83-90. PubMed ID: 34709591
[TBL] [Abstract][Full Text] [Related]
2. TransCon human growth hormone for children with growth hormone deficiency: a technology evaluation.
Dos Santos JBR; Da Silva MRR
Expert Opin Drug Deliv; 2022 Jan; 19(1):1-7. PubMed ID: 34996331
[TBL] [Abstract][Full Text] [Related]
3. Switching to Weekly Lonapegsomatropin from Daily Somatropin in Children with Growth Hormone Deficiency: The fliGHt Trial.
Maniatis AK; Nadgir U; Saenger P; Reifschneider KL; Abuzzahab J; Deeb L; Fox LA; Woods KA; Song W; Mao M; Chessler SD; Komirenko AS; Shu AD; Casella SJ; Thornton PS
Horm Res Paediatr; 2022; 95(3):233-243. PubMed ID: 35263755
[TBL] [Abstract][Full Text] [Related]
4. Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial.
Thornton PS; Maniatis AK; Aghajanova E; Chertok E; Vlachopapadopoulou E; Lin Z; Song W; Christoffersen ED; Breinholt VM; Kovalenko T; Giorgadze E; Korpal-Szczyrska M; Hofman PL; Karpf DB; Shu AD; Beckert M
J Clin Endocrinol Metab; 2021 Oct; 106(11):3184-3195. PubMed ID: 34272849
[TBL] [Abstract][Full Text] [Related]
5. Spotlight on Lonapegsomatropin Once-Weekly Injection and Its Potential in the Treatment of Growth Hormone Deficiency in Pediatric Patients.
Miller BS; Yuen KCJ
Drug Des Devel Ther; 2022; 16():2055-2066. PubMed ID: 35791404
[TBL] [Abstract][Full Text] [Related]
6. Safety and Efficacy of Lonapegsomatropin in Children With Growth Hormone Deficiency: enliGHten Trial 2-Year Results.
Maniatis AK; Casella SJ; Nadgir UM; Hofman PL; Saenger P; Chertock ED; Aghajanova EM; Korpal-Szczyrska M; Vlachopapadopoulou E; Malievskiy O; Chaychenko T; Cappa M; Song W; Mao M; Mygind PH; Smith AR; Chessler SD; Komirenko AS; Beckert M; Shu AD; Thornton PS
J Clin Endocrinol Metab; 2022 Jun; 107(7):e2680-e2689. PubMed ID: 35428884
[TBL] [Abstract][Full Text] [Related]
7. Average IGF-1 Prediction for Once-Weekly Lonapegsomatropin in Children With Growth Hormone Deficiency.
Lin Z; Shu AD; Bach M; Miller BS; Rogol AD
J Endocr Soc; 2022 Jan; 6(1):bvab168. PubMed ID: 34913019
[TBL] [Abstract][Full Text] [Related]
8. Weekly Growth Hormone (Lonapegsomatropin) Causes Severe Transient Hyperglycemia in a Child with Obesity.
Alkhatib EH; Dauber A; Estrada DE; Majidi S
Horm Res Paediatr; 2023; 96(5):542-546. PubMed ID: 37015214
[TBL] [Abstract][Full Text] [Related]
9. Lonapegsomatropin (Skytrofa) for growth hormone deficiency.
Med Lett Drugs Ther; 2022 Feb; 64(1643):20-22. PubMed ID: 35134048
[No Abstract] [Full Text] [Related]
10. Health-related quality of life in pre-pubertal children with pediatric growth hormone deficiency: 12-month results from a phase 3 clinical trial of once-weekly somatrogon versus once-daily somatropin.
Loftus J; Quitmann J; Valluri SR
Curr Med Res Opin; 2024 Feb; 40(2):175-184. PubMed ID: 38053515
[TBL] [Abstract][Full Text] [Related]
11. Developments in the Management of Growth Hormone Deficiency: Clinical Utility of Somapacitan.
Miller BS; Blair J; Horikawa R; Linglart A; Yuen KCJ
Drug Des Devel Ther; 2024; 18():291-306. PubMed ID: 38333899
[TBL] [Abstract][Full Text] [Related]
12. Somatrogon: First Approval.
Lamb YN
Drugs; 2022 Feb; 82(2):227-234. PubMed ID: 35041176
[TBL] [Abstract][Full Text] [Related]
13. What do we do now that the long-acting growth hormone is here?
Miller BS
Front Endocrinol (Lausanne); 2022; 13():980979. PubMed ID: 36072938
[TBL] [Abstract][Full Text] [Related]
14. Treatment Burden of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Randomized Study.
Maniatis AK; Carakushansky M; Galcheva S; Prakasam G; Fox LA; Dankovcikova A; Loftus J; Palladino AA; de Los Angeles Resa M; Turich Taylor C; Dattani MT; Lebl J
J Endocr Soc; 2022 Oct; 6(10):bvac117. PubMed ID: 36101713
[TBL] [Abstract][Full Text] [Related]
15. Relative Bioavailability of a Single 4-mg Dose of Somatropin Administered by Subcutaneous Injection or by Needle-free Device and Coadministered With the Growth Hormone Inhibitor Octreotide Acetate in Healthy Adult Subjects.
Brimhall DB; Petri N; D'Angelo P
Clin Ther; 2018 May; 40(5):741-751. PubMed ID: 29699852
[TBL] [Abstract][Full Text] [Related]
16. Prospects for the development of long-acting formulations of human somatropin.
Jostel A; Shalet SM
Treat Endocrinol; 2006; 5(3):139-45. PubMed ID: 16677056
[TBL] [Abstract][Full Text] [Related]
17. A long-acting human growth hormone (Nutropin Depot): efficacy and safety following two years of treatment in children with growth hormone deficiency.
Silverman BL; Blethen SL; Reiter EO; Attie KM; Neuwirth RB; Ford KM
J Pediatr Endocrinol Metab; 2002 May; 15 Suppl 2():715-22. PubMed ID: 12092685
[TBL] [Abstract][Full Text] [Related]
18. Letter to the Editor From Sävendahl et al.: "Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial".
Sävendahl L; Battelino T; Brod M; Højby Rasmussen M; Juul Kildemoes R; Saenger P
J Clin Endocrinol Metab; 2022 Jan; 107(2):e888-e889. PubMed ID: 34626473
[No Abstract] [Full Text] [Related]
19. Response to Letter to the Editor From L. Sävendahl et al: "Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial".
Thornton PS; Maniatis AK; Aghajanova E; Chertok E; Vlachopapadopoulou E; Lin Z; Song W; Christoffersen ED; Breinholt VM; Kovalenko T; Giorgadze E; Korpal-Szczyrska M; Hofman PL; Karpf DB; Shu AD; Beckert M
J Clin Endocrinol Metab; 2022 Feb; 107(3):e1333-e1334. PubMed ID: 34626470
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
